<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GRIS-PEG- griseofulvin tablet, film coated </strong><br>PEDINOL PHARMACAL INC.<br></p></div>
<h1>Gris-PEG<span class="Sup">®</span><br>(griseofulvin ultramicrosize)<br>Tablets, USP<br>125 mg; 250 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Gris-PEG<span class="Sup">®</span> Tablets contain ultramicrosize
							crystals of griseofulvin, an antibiotic derived from a species of
								<span class="Italics">Penicillium</span>.</p>
<p>Each Gris-PEG<span class="Sup">®</span> tablet contains:</p>
<p><span class="Italics">Active Ingredient:</span> griseofulvin
							ultramicrosize .... 125 mg</p>
<p><span class="Italics">Inactive Ingredients:</span> colloidal
							silicon dioxide, lactose, magnesium stearate, methylcellulose,
							methylparaben, polyethylene glycol 400 and 8000, povidone, and titanium
							dioxide.</p>
<p>or</p>
<p><span class="Italics">Active Ingredient:</span> griseofulvin
							ultramicrosize .... 250 mg</p>
<p><span class="Italics">Inactive Ingredients:</span> colloidal
							silicon dioxide, magnesium stearate, methylcellulose, methylparaben,
							polyethylene glycol 400 and 8000, povidone, sodium lauryl sulfate, and
							titanium dioxide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<h1>ACTION</h1>
<div class="Section" data-sectionCode="49489-8">
<a name="section-2.1"></a><p></p>
<h2>Microbiology </h2>
<p class="First">Griseofulvin is fungistatic with <span class="Italics">in vitro</span> activity against
									various species of <span class="Italics">Microsporum,
										Epidermophyton</span> and <span class="Italics">Trichophyton</span>. It has no effect on bacteria or
									other genera of fungi.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Following oral administration, griseofulvin is deposited
									in the keratin precursor cells and has a greater affinity for
									diseased tissue. The drug is tightly bound to the new keratin
									which becomes highly resistant to fungal invasions.</p>
<p>The efficiency of gastrointestinal absorption of
									ultramicrocrystalline griseofulvin is approximately one and
									one-half times that of the conventional microsize griseofulvin.
									This factor permits the oral intake of two-thirds as much
									ultramicrocrystalline griseofulvin as the microsize form.
									However, there is currently no evidence that this lower dose
									confers any significant clinical differences with regard to
									safety and/or efficacy.</p>
<p>In a bioequivalence study conducted in healthy volunteers
									(N=24) in the fasted state, 250 mg ultramicrocrystalline
									griseofulvin tablets were compared with 250 mg
									ultramicrocrystalline griseofulvin tablets that were physically
									altered (crushed) and administered with applesauce. The 250 mg
									ultramicrocrystalline griseofulvin tablets were found to be
									bioequivalent to the physically altered (crushed) 250 mg
									ultramicrocrystalline griseofulvin tablets (See <a href="#table1">Table 1</a>).</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1: Mean (± SD) of the Pharmacokinetic
										Parameters for Griseofulvin administered in applesauce as a
										Single Dose of Gris-PEG<span class="Sup">®</span> 250-mg Tablets
										Uncrushed and Crushed to fasted Healthy Volunteers (N=24)</span></caption>
<col align="left" width="16%">
<col align="left" width="42%">
<col align="left" width="42%">
<thead><tr class="First Last">
<th class="Botrule Lrule" align="left">  </th>
<th class="Botrule Lrule" align="left">250 mg
												Ultramicrocrystalline<br>Griseofulvin Tablets
												Unaltered</th>
<th class="Botrule Lrule Rrule" align="left">250 mg
												Ultramicrocrystalline<br>Griseofulvin Tablets
												Physically Altered (Crushed and in Applesauce)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="left">Cmax<br>(ng/mL)</td>
<td class="Botrule Lrule" align="left">600.61 (± 167.6)</td>
<td class="Botrule Lrule Rrule" align="left">672.61 (±
												146.2)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left">Tmax (hr)</td>
<td class="Botrule Lrule" align="left">4.04 (± 2.2)</td>
<td class="Botrule Lrule Rrule" align="left">3.08 (±
												1.02)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left">AUC<br>(ng.hr/mL)</td>
<td class="Botrule Lrule" align="left">8618.89 (±
												1907.2)</td>
<td class="Botrule Lrule Rrule" align="left">9023.71 (±
												1911.5)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS</h1>
<p class="First">Gris-PEG<span class="Sup">®</span> (griseofulvin ultramicrosize) is
							indicated for the treatment of the following ringworm <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>; <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span>
							corporis (ringworm of the body), <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> (athlete's foot), <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span>
							cruris (ringworm of the groin and thigh), <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> barbae (barber's <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itch</span>),
							<span class="product-label-link" type="condition" conceptid="4182398" conceptname="Tinea capitis">tinea capitis</span> (ringworm of the scalp), and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium (<span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>,
							ringworm of the nails), when caused by one or more of the following
							genera of fungi: <span class="Italics">Trichophyton rubrum,
								Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton
								interdigitalis,Trichophyton verrucosum, Trichophyton megnini,
								Trichophyton gallinae, Trichophyton crateriform, Trichophyton
								sulphureum, Trichophyton schoenleini, Microsporum audouini,
								Microsporum canis, Microsporum gypseum</span> and <span class="Italics">Epidermophyton floccosum</span>. NOTE: Prior
							to therapy, the type of fungi responsible for the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be
							identified. The use of the drug is not justified in minor or trivial
							<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> which will respond to topical agents alone. Griseofulvin is
								<span class="Italics">not</span> effective in the
							following: <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> (<span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>),
							<span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="436020" conceptname="Actinomycotic infection">actinomycosis</span>, sporotrichosis, chromoblastomycosis,
							<span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, North American <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>, <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">cryptococcosis</span>
							(torulosis), <span class="product-label-link" type="condition" conceptid="134870" conceptname="Pityriasis versicolor">tinea versicolor</span> and <span class="product-label-link" type="condition" conceptid="4104668" conceptname="Nocardiosis">nocardiosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Two cases of conjoined twins have been reported since 1977 in
							patients taking griseofulvin during the first trimester of pregnancy.
							Griseofulvin should not be prescribed to pregnant patients. If the
							patient becomes pregnant while taking this drug, the patient should be
							apprised of the potential hazard to the fetus.</p>
<p>This drug is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span> or
							hepatocellular failure and in individuals with a history of
							<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to griseofulvin.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> Usage</h2>
<p class="First">Safety and efficacy of griseofulvin for prophylaxis of
									<span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (e.g. <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>,
									<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> have been
									reported with griseofulvin use. These reactions may be serious
									and may result in hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. If severe skin
									reactions occur, griseofulvin should be discontinued (see
										<a href="#Adverse">ADVERSE REACTIONS</a>
									section).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Elevations in AST, ALT, bilirubin, and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> have been
									reported with griseofulvin use. These reactions may be serious
									and may result in hospitalization or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients should be
									monitored for hepatic adverse events and discontinuation of
									griseofulvin considered if warranted (see <a href="#Adverse">ADVERSE REACTIONS</a>
								section).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-5.4"></a><p></p>
<h2>Animal Toxicology</h2>
<p class="First">Chronic feeding of griseofulvin, at levels ranging from
									0.5%-2.5% of the diet resulted in the development of liver
									tumors in several <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of mice, particularly in males.
									Smaller particle sizes result in an enhanced effect. Lower oral
									dosage levels have not been tested. Subcutaneous administration
									of relatively small doses of griseofulvin once a week during the
									first three weeks of life has also been reported to induce
									hepatomata in mice. <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">Thyroid tumors</span>, mostly <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> but some
									carcinomas, have been reported in male rats receiving
									griseofulvin at levels of 2.0%, 1.0% and 0.2% of the diet, and
									in female rats receiving the two higher dose levels. Although
									studies in other animal species have not yielded evidence of
									tumorigenicity, these studies were not of adequate design to
									form a basis for conclusion in this regard. In subacute toxicity
									studies, orally administered griseofulvin produced
									hepatocellular <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> in mice, but this has not been seen in
									other species. Disturbances in porphyrin metabolism have been
									reported in griseofulvin-treated laboratory animals.
									Griseofulvin has been reported to have a colchicine-like effect
									on mitosis and cocarcinogenicity with methylcholanthrene in
									cutaneous tumor induction in laboratory animals.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-5.5"></a><p></p>
<h2>Usage in Pregnancy</h2>
<p class="First">See <a href="#Contraindications">CONTRAINDICATIONS</a> section.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-5.6"></a><p></p>
<h2>Animal Reproduction Studies</h2>
<p class="First">It has been reported in the literature that griseofulvin
									was found to be embryotoxic and teratogenic on oral
									administration to pregnant rats. Pups with abnormalities have
									been reported in the litters of a few bitches treated with
									griseofulvin. Suppression of spermatogenesis has been reported
									to occur in rats, but investigation in man failed to confirm
									this.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">Patients on prolonged therapy with any potent medication should
							be under close observation. Periodic monitoring of organ system
							function, including renal, hepatic and hematopoietic, should be done.
							Since griseofulvin is derived from species of <span class="Italics">Penicillium</span>, the possibility of
							cross-sensitivity with penicillin exists; however, known
							penicillin-sensitive patients have been treated without difficulty.
							Since a <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span> is occasionally associated with
							griseofulvin therapy, patients should be warned to avoid exposure to
							intense natural or artificial sunlight. Occasionally slight
							abnormalities in liver enzymes (irrespective of drug relationship) were
							reported with an incidence of less than 1%, specifically elevated ALT
							and/orAST. The majority of subjects with elevated liver enzymes also had
							concomitant medical conditions and were taking other drugs that may have
							increased the propensity for elevated values. When follow-up was
							provided, changes in elevated liver enzymes appeared to be reversible.
							<span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">Lupus erythematosus</span> or lupus-like syndromes have been reported in
							patients receiving griseofulvin. Griseofulvin decreases the activity of
							warfarin-type anticoagulants so that patients receiving these drugs
							concomitantly may require dosage adjustment of the anticoagulant during
							and after griseofulvin therapy. Barbiturates usually depress
							griseofulvin activity and concomitant administration may require a
							dosage adjustment of the antifungal agent. There have been reports in
							the literature of possible interactions between griseofulvin and oral
							contraceptives. The effect of alcohol may be potentiated by
							griseofulvin, producing such effects as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and
						flush.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Adverse"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">There have been post-marketing reports of severe skin and hepatic
							adverse events associated with griseofulvin use (see <a href="#Warnings">WARNINGS</a> section).</p>
<p>When adverse reactions occur, they are most commonly of the
							<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> type such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>
							multiform-like drug reactions, and rarely, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, and may
							necessitate withdrawal of therapy and appropriate countermeasures.
							<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> of the hands and feet have been reported after extended
							therapy. Other side effects reported occasionally are <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral thrush</span>,
							<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>,
							<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, and impairment of performance of
							routine activities. <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> have been reported
							rarely. Administration of the drug should be discontinued if
							<span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span> occurs. When rare, serious reactions occur with
							griseofulvin, they are usually associated with high dosages, long
							periods of therapy, or both.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Accurate diagnosis of infecting organism is essential.
							Identification should be made either by direct microscopic examination
							of a mounting of infected tissue in a solution of potassium hydroxide or
							by culture on an appropriate medium. Medication must be continued until
							the infecting organism is completely eradicated as indicated by
							appropriate clinical or laboratory examination. Representative treatment
							periods are <span class="product-label-link" type="condition" conceptid="4182398" conceptname="Tinea capitis">tinea capitis</span>, 4 to 6 weeks; <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis, 2 to 4 weeks;
							<span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>, 4 to 8 weeks; <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium-depending on rate of
							growth-fingernails, at least 4 months; toenails, at least 6 months.</p>
<p>General measures in regard to hygiene should be observed to
							control sources of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or reinfection. Concomitant use of
							appropriate topical agents is usually required, particularly in
							treatment of <span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span>. In some forms of athlete's foot, yeasts and
							bacteria may be involved as well as fungi. Griseofulvin will not
							eradicate the bacterial or monilial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Gris-PEG<span class="Sup">®</span> tablets may be swallowed whole or
							crushed and sprinkled onto 1 tablespoonful of applesauce and swallowed
							immediately without chewing.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Adults</h2>
<p class="First">Daily administration of 375 mg (as a single dose or in
									divided doses) will give a satisfactory response in most
									patients with <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> corporis, <span class="product-label-link" type="condition" conceptid="4160328" conceptname="Tinea cruris">tinea cruris</span>, and <span class="product-label-link" type="condition" conceptid="4182398" conceptname="Tinea capitis">tinea capitis</span>.
									For those <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> more difficult to eradicate, such as
									<span class="product-label-link" type="condition" conceptid="133141" conceptname="Tinea pedis">tinea pedis</span> and <span class="product-label-link" type="condition" conceptid="135473" conceptname="Dermatophytosis">tinea</span> unguium, a divided dose of 750 mg is
									recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Approximately 3.3 mg per pound of body weight per day of
									ultramicrosize griseofulvin is an effective dose for most
									pediatric patients. On this basis, the following dosage schedule
									is suggested: Children weighing 35-60 pounds - 125 mg to 187.5
									mg daily. Pediatric patients weighing over 60 pounds - 187.5 mg
									to 375 mg daily. Children and infants 2 years of age and younger
									- dosage has not been established.</p>
<p>Clinical experience with griseofulvin in children with
									<span class="product-label-link" type="condition" conceptid="4182398" conceptname="Tinea capitis">tinea capitis</span> indicates that a single daily dose is effective.
									Clinical relapse will occur if the medication is not continued
									until the infecting organism is eradicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Gris-PEG<span class="Sup">®</span> (griseofulvin ultramicrosize)
							Tablets, 125 mg, white scored, elliptical-shaped, embossed "Gris-PEG" on
							one side and "125" on the other. Gris-PEG<span class="Sup">®</span>
							(griseofulvin ultramicrosize) Tablets, 250 mg, white scored,
							capsule-shaped, embossed "Gris-PEG" on one side and "250" on the other.
							The 125 mg strength is available in bottles of 100 (NDC 0884-0763-04).
							The 250 mg strength is available in bottles of 100 (NDC
							0884-0773-04). Both strengths are
							film-coated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">Rx ONLY</span></p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11"></a><p></p>
<h1>STORAGE</h1>
<p class="First">Store Gris-PEG <span class="Sup">®</span> tablets at controlled room
							temperature 15° - 30°C (59° - 86°F)
							in tight, light-resistant containers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured for:<br>PEDINOL PHARMACAL INC.<br>Farmingdale, NY
							11735 U.S.A.<br>By:<br>NOVARTIS CONSUMER HEALTH INC.<br>Lincoln, NE
							68501</p>
<p>Printed in U.S.A.</p>
<p>REV 10/10</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 125
								mg 100 count</span></p>
<p>NDC 0884-0763-04
							      Rx Only</p>
<p><span class="Bold">GRIS•PEG<span class="Sup">®</span></span><br> (griseofulvin
							ultramicrosize)<br>Tablets USP</p>
<table><tbody class="Headless"><tr class="First Last">
<td>125 mg</td>
<td>     </td>
<td>100 Tablets</td>
</tr></tbody></table>
<div class="Figure"><img alt="Image of Carton Label - 125 mg, 100 Count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=20aa6571-ee10-4dc1-9be9-018aa0a680fc&amp;name=gris-peg-1.jpg"></div>
<p><span class="Bold">PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 250
								mg 100 count</span></p>
<p>NDC 0884-0773-04
							      Rx Only</p>
<p><span class="Bold">GRIS•PEG<span class="Sup">®</span></span><br> (griseofulvin
							ultramicrosize)<br>Tablets USP</p>
<table><tbody class="Headless"><tr class="First Last">
<td>250 mg</td>
<td>     </td>
<td>100 Tablets</td>
</tr></tbody></table>
<div class="Figure"><img alt="Image of Carton Label - 250 mg, 100 Count" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=20aa6571-ee10-4dc1-9be9-018aa0a680fc&amp;name=gris-peg-2.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GRIS-PEG 		
					</strong><br><span class="contentTableReg">griseofulvin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0884-0773</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>griseofulvin</strong> (griseofulvin) </td>
<td class="formItem">griseofulvin</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylcellulose (15 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (CAPSULE-SHAPED) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GRIS;PEG;250</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0884-0773-04</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050475</td>
<td class="formItem">04/16/1975</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GRIS-PEG 		
					</strong><br><span class="contentTableReg">griseofulvin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0884-0763</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>griseofulvin</strong> (griseofulvin) </td>
<td class="formItem">griseofulvin</td>
<td class="formItem">125 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>methylcellulose (15 CPS)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycol 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 8000</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (ELLIPTICAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GRIS;PEG;125</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0884-0763-04</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050475</td>
<td class="formItem">04/16/1975</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PEDINOL PHARMACAL INC.
							(064737125)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Novartis</td>
<td class="formItem"></td>
<td class="formItem">129836151</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1b0bebd2-ab7f-4d13-84fc-9b1c5b97d96f</div>
<div>Set id: 20aa6571-ee10-4dc1-9be9-018aa0a680fc</div>
<div>Version: 4</div>
<div>Effective Time: 20101013</div>
</div>
</div> <div class="DistributorName">PEDINOL PHARMACAL INC.</div></p>
</body></html>
